194
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Natural IgM antibodies in the immune defence against neoehrlichiosis

, , , , , & show all
Pages 809-816 | Received 07 Mar 2017, Accepted 08 Jun 2017, Published online: 06 Jul 2017
 

Abstract

Background: Neoehrlichiosis is an infectious disease caused by the tick-borne bacterium “Candidatus Neoehrlichia mikurensis”. Splenectomy and rituximab therapies are risk factors for severe neoehrlichiosis. Our aim was to examine if neoehrlichiosis patients had low levels of natural IgM antibodies and/or were hypogammaglobulinemic, and if such deficiencies were associated with asplenia and vascular complications.

Methods: Neoehrlichiosis patients (n = 9) and control subjects (n = 10) were investigated for serum levels of IgG, IgA, and IgM, and for levels of natural IgM antibodies to pneumococcal polysaccharides (6B, 14), and to the malondialdehyde acetaldehyde epitope of oxidized LDL. The multivariate method Projection to Latent Structures was used to analyze the data.

Results: The levels of natural IgM antibodies of various specificities were decreased or not measurable in half of the studied patients with neoehrlichiosis. Only one patient and one control subject were hypogammaglobulinemic. An inverse relationship was noted between the levels of natural IgM antibodies and the development of deep vein thrombosis. Unexpectedly, no association was seen between having or not having a spleen and the levels of natural IgM antibody levels in the circulation.

Conclusions: Neither hypogammaglobulinemia nor lack of natural IgM antibodies alone predisposes for severe neoehrlichiosis. The importance of the spleen in the immune defence against Ca. N. mikurensis probably lies in its capacity to generate or maintain specific antibodies.

Disclosure statement

None of the authors report conflicts of interest relevant to this study.

Additional information

Funding

The work was supported by the Swedish Cancer and Allergy Foundation (No. 149781), ALF Project grant (No. 71580), Västra Götaland Research and Development grant (No. 94510), Swedish Cancer Association and National Institute for Health Research UK.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.